Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

National uniformity compromise obtainable to bring FDA reform bill to floor -- Sen. Kennedy.

This article was originally published in The Tan Sheet

Executive Summary

NATIONAL UNIFORMITY "COMPROMISES CAN BE REACHED," SEN. KENNEDY told Senate Majority Leader Trent Lott (R-Miss.) in floor remarks made July 31 prior to the August congressional recess. Sen. Edward Kennedy (D-Mass.), the Labor & Human Resources Committee ranking minority member, suggested that "acceptable compromises can be reached" in negotiations on federal pre-emption of states' authority to regulate OTCs and cosmetics and on device-related provisions in Sen. James Jeffords' (R-Vt.) FDA reform bill (S 830).

You may also be interested in...



PDUFA III Or Hatch/Waxman II?: Payors Urge Fix For Generic “Loopholes”

Supporters of the generic industry's Hatch/Waxman agenda are eyeing the Prescription Drug User Fee Act reauthorization as a potential vehicle for reform measures

PDUFA III Or Hatch/Waxman II?: Payors Urge Fix For Generic “Loopholes”

Supporters of the generic industry's Hatch/Waxman agenda are eyeing the Prescription Drug User Fee Act reauthorization as a potential vehicle for reform measures

PDUFA III Or Hatch/Waxman II?: Payors Urge Fix For Generic “Loopholes”

Supporters of the generic industry's Hatch/Waxman agenda are eyeing the Prescription Drug User Fee Act reauthorization as a potential vehicle for reform measures

Topics

UsernamePublicRestriction

Register

PS087407

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel